ai-for-science
AI Is Rewriting the Odds of Drug Development
a16z argues AI could alter drug hit rates and development timelines, but without clinical validation it remains a commercial option, not a proven infl
2 articles tagged with this topic
a16z argues AI could alter drug hit rates and development timelines, but without clinical validation it remains a commercial option, not a proven infl
Qwen's new model hits 2.4T parameters; weights alone take 1.2TB. Local AI is becoming a luxury — enterprise private deployment just got redrawn.